Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

November 2nd, 2020

Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

Bridgewater, NJ – November 2, 2020 — Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the second renewal of a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). The agreement enables NCATS’s use of the company’s Quatramer™ drug delivery technology.  This technology will be used to develop formulations of HDAC6-PI3Kδ dual inhibitors for the treatment of rare cancers, including acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL).

Studies have shown that by disrupting multiple compensatory cyto-protective pathways, HDAC6-PI3Kδ dual inhibitors might have potential therapeutic value.  The primary objective of the study is encapsulation of NCATS’s developed HDAC6-PI3Kδ dual inhibitors into Hillstream’s proprietary, nanoparticle tumor infiltrating Quatramer suspension to assist with enhanced and safer delivery into malignant cells.

“Our collaboration through the CRADA program with NCATS demonstrates a vital external validation of our Quatramer platform and of its potential utility in treating a number of rare cancers,” stated Randy Milby, Founder and CEO of Hillstream BioPharma.  “We believe there remains a large unmet need across a variety of cancers, and we look forward to continuing our work to provide viable and safe treatment options for these cancer types.”

About Quatramer™ Technology

Hillstream BioPharma’s proprietary Quatramer™ technology, developed by experienced cancer researchers, are designed with specific physico-chemical parameters to target specified cells or tissues and converge a therapeutic payload at the site of disease to boost efficacy while abating adverse effects on healthy tissue. The strategy is to leverage the platform to develop a pipeline of Quatramer™, an enhanced sustained injectable system enabling novel therapeutics development, initially in the oncology space. Hillstream BioPharma is using the technology to develop a pipeline of unique drugs which leverages the platform via directed intranuclear and intracellular delivery of small molecules, peptides, genes, other macromolecules and biologics to the tumor cell while significantly minimizing exposure to normal tissues.

About Hillstream BioPharma, Inc.

Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) is a clinical stage platform company developing Quatramer™.  The Company is advancing lead candidates, including novel small molecules and proprietary DNA expression vectors, which encode inflammatory cytokines directly into the tumor’s genome.  The lead drug candidate, HSB-1216, is in IND-enabling studies and can be developed in the clinic in 2021 for small cell lung cancer (SCLC) and triple-negative breast cancer. The Company has achieved orphan drug designation in SCLC for HSB-1216’s payload and plans to develop other Quatramer™-based compounds with therapeutic cargoes from the product pipeline.  These include DNA-based contents which hijack the tumor’s genetic code and kill the tumor from within by generating an array of cancer killing cytokines, such as tumor necrosis factor alpha or TNF-a and interleukin-2 (IL-2).  The platform’s tunability stems from the fact that the system can be modified and adjusted to deliver single or multiple ratios of payloads in order to optimize synergistic mechanisms of action in lower doses in order to eradicate rare cancers and devastating tumors with minimal or no treatment options. For more information, please visit tharimmune.com.

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic.  Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

Hillstream BioPharma, Inc.
Randy Milby
Founder & CEO
Hillstream Biopharma, Inc.
Tel: +1 302.743.2995
Email: rmilby@tharimmune.com

Investor Contact
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications, Inc.
Tel: +1 917.214.3514
Email: jzimmons@zimmonsic.com